Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial

Lee, Dong-Hyun; Kim, Moo Hyun; Park, Tae-Ho; Park, Jong Sung; Park, Kyungil; Zhang, Hong-Zhe; Seo, Jeong-Min; Lee, Michael S.
April 2013
Trials;2013, Vol. 14 Issue 1, p1
Academic Journal
Background: Patients with reduced responsiveness to clopidogrel often have diminished platelet inhibition, a factor associated with increased rates of major adverse cardiovascular events. Clinical trials that have focused on reducing high on-treatment platelet reactivity (HPR) with an additional loading dose of clopidogrel have reported varying effects. Prasugrel, a newer thienopyridine, exhibits a more consistent antiplatelet effect and more rapid onset time when compared to clopidogrel. We hypothesize that prasugrel reloading would be more effective than clopidogrel reloading in patients with HPR after an initial loading dose of clopidogrel. Method/Design: Comparison of Prasugrel and Clopidogrel Reloading on High Platelet Reactivity in Clopidogrelloaded Patients Undergoing Percutaneous Coronary Intervention (PRAISE-HPR) is a prospective, randomized, openlabel, active controlled study. A total of 76 patients undergoing percutaneous coronary intervention (PCI), with HPR after administration of a loading dose of clopidogrel will be randomly assigned to either prasugrel or clopidogrel groups, and patients in each group will be reloaded with 20 mg of prasugrel or 300 mg of clopidogrel. The primary endpoint will be HPR at 24 hours after PCI, as determined by the VerifyNow assay during the study period. The rate of sustained high platelet reactivity and 30-day clinical outcomes will also be measured. Discussion: PRAISE-HPR is a randomized controlled clinical trial to investigate the efficacy and safety of reloading prasugrel and clopidogrel in suppressing residual high platelet reactivity. The results will be made publicly available in the year 2013.


Related Articles

  • The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes. Panattoni, Laura; Brown, Paul; Ao, Braden; Webster, Mark; Gladding, Patrick // PharmacoEconomics;2012, Vol. 30 Issue 11, p1067 

    Background: A recent clinical trial has demonstrated that patients with acute coronary syndromes (ACS) and the reduced function allele CYP2C19*2 (*2 allele), who are treated with thienopyridines, have an increased risk of adverse cardiac events with clopidogrel, but not with prasugrel. The...

  • Antiplatelet Therapy in Women With Acute Coronary Syndrome. Foody, JoAnne // Journal of Family Practice;Feb2014 Supplement, Vol. 63, pS3 

    The article focuses on the use of antiplatelet agents, prasugrel and clopidogrel, for acute coronary syndrome (ACS) treatment and the differences between women and men in safety and efficacy of those agents. Topics discussed include ACS gender-related differences, antiplatelet agents clinical...

  • Clopidogrel vs. Prasugrel vs. Ticagrelor in Patients with Acute Coronary Syndromes (ACS) Treated with Percutaneous Coronary Intervention (PCI). Yudi, M.; Andrianopoulos, N.; Tsang, D.; Clark, D.; Duffy, S.; Brennan, A.; Yip, T.; Yan, B.; Freeman, M.; Oqueli, E.; Farouque, O.; Reid, C.; Ajani, A. // Heart, Lung & Circulation;2015 Supplement 3, Vol. 24, pS267 

    No abstract available.

  • Prasugrel: A Novel Antiplatelet Therapy for Acute Coronary Syndromes. Singh, Sarabjeet; Singh, Mukesh; Pahwa, Harneet; Jawad, Evyan; Khosla, Sandeep; Arora, Rohit // Recent Patents on Cardiovascular Drug Discovery;Nov2009, Vol. 4 Issue 3, p192 

    Dual antiplatelet therapy has been the standard therapy in the management of patients with acute coronary syndrome. It involves the use of aspirin along with a thienopyridine, like clopidogrel. However, it has been found that these patients had recurrent ischemic attacks even when on the dual...

  • New P2Y12 inhibitors.  // Heart;Aug2011, Vol. 97 Issue 15, p1262 

    The article focuses on the platelet receptor P2Y12 inhibitors, which transform the efficacy of pharmacotherapy for percutaneous coronary intervention (PCI) and acute coronary syndromes (ACS). It says that the ticagrelor and prasugrel inhibitors provide high levels of P2Y12 inhibition than...

  • TRILOGY ACS Outcomes. Alexander, Lori // MD Conference Express;Oct2012, p16 

    The article discusses the findings from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) study. Medical director Matthew T. Roe has stressed the importance of the study because majority of patients with ACS are managed...

  • Recent advances in antithrombotic therapy after acute coronary syndrome. Matteau, Alexis; Bhatt, Deepak L. // CMAJ: Canadian Medical Association Journal;5/13/2014, Vol. 186 Issue 8, p589 

    The article examines the advances in antiplatelet and anticoagulant agents used in the pharmacological treatment of acute coronary syndrome as of 2014. Points discussed include the proper administration of acetylsalicylic acid (ASA) to patients with acute coronary syndrome, the additional...

  • Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. Klingenberg, Roland; Heg, Dik; Räber, Lorenz; Carballo, David; Nanchen, David; Gencer, Baris; Auer, Reto; Jaguszewski, Milosz; Stähli, Barbara E.; Jakob, Philipp; Templin, Christian; Stefanini, Giulio G.; Meier, Bernhard; Vogt, Pierre; Roffi, Marco; Maier, Willibald; Landmesser, Ulf; Rodondi, Nicolas; Mach, François; Windecker, Stephan // Heart;Jun2015, Vol. 101 Issue 11, p854 

    Objective To assess safety up to 1 year of follow-up associated with prasugrel and clopidogrel use in a prospective cohort of patients with acute coronary syndromes (ACS). Methods Between 2009 and 2012, 2286 patients invasively managed for ACS were enrolled in the multicentre Swiss ACS Bleeding...

  • Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. Teng, Renli // Clinical Pharmacokinetics;Nov2015, Vol. 54 Issue 11, p1125 

    Despite advancements in treatments for acute coronary syndromes over the last 10 years, they continue to be life-threatening disorders. Currently, the standard of treatment includes dual antiplatelet therapy consisting of aspirin plus a P2Y12 receptor antagonist. The thienopyridine class of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics